Compare · GRI vs LLY
GRI vs LLY
Side-by-side comparison of GRI Bio Inc. (GRI) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRI and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.04T, about 316532.9x GRI ($3.3M).
- Over the past year, GRI is down 95.2% and LLY is up 42.3% - LLY leads by 137.6 points.
- LLY has been more active in the news (13 items in the past 4 weeks vs 2 for GRI).
- LLY has more recent analyst coverage (25 ratings vs 1 for GRI).
- Company
- GRI Bio Inc.
- Eli Lilly and Company
- Price
- $1.80-3.99%
- $1107.83+0.42%
- Market cap
- $3.3M
- $1.04T
- 1M return
- -17.95%
- +6.33%
- 1Y return
- -95.22%
- +42.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 13
- Recent ratings
- 1
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest GRI
- GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
- GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
- GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
- Amendment: SEC Form SCHEDULE 13G/A filed by GRI Bio Inc.
- SEC Form 10-Q filed by GRI Bio Inc.
- GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
- Amendment: SEC Form SCHEDULE 13G/A filed by GRI Bio Inc.
- GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Latest LLY
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials